• Histocell SL

  Participated · Equity · Sep 2016

  Histocell develops regenerative medicine and cell-therapy products, originating from research groups at the University of the Basque Country. Founded in 2005, the company integrated into the Noray Biosciences Group and is based in Bizkaia. It has around 10 employees and recently opened a production center in Larrabetzu following a €1.6M investment. The firm operates in the biotechnology/genetic engineering sector and focuses on translating cell-therapy research into products. Ownership remains concentrated: founders together with NorayBio and Orza retain more than 40% of the capital. The company completed a recent capital increase to support its development and internationalization plans. Founded in 2005 from research teams at the University of the Basque Country, Histocell develops regenerative‑medicine and cell‑therapy products and medical devices for aesthetic medicine. The company incubated at the Parque Tecnológico de Bizkaia and later integrated into the Noray Biosciences Group. Its product portfolio includes sanitary/medical devices aimed at aesthetic applications, and its first marketed product is Reoxcare. Histocell plans to use new funding to continue research, advance clinical trials, complete final development of aesthetic medical products, and support commercialization. Financially, the company completed a €4 million capital increase in which new investors joined the shareholder base. Shareholders include GCRPV (Ezten), Seed Capital Bizkaia, Noray Biosciences Group, Orza and business angels. Histocell develops Reoxcare, an active wound dressing that targets antioxidation to accelerate the natural healing of hard-to-heal wounds. Reoxcare has been tested successfully on various chronic and acute difficult-to-heal wounds. The company planned a commercial launch at the end of 2015 pending receipt of a CE mark. Histocell has secured commercialization agreements, including one with Luqa Pharma for China, Hong Kong and Macao, and is negotiating entry into other European and Asian markets. To support internationalization, Histocell closed the first tranche of a planned €4M financing round, raising €2.5M from its main shareholders and a new investor. The funds are intended to finance the international market rollout of Reoxcare. Histocell develops cell‑based medicines aimed at treating pulmonary diseases, notably idiopathic pulmonary fibrosis. The company has a license agreement with Hospital Clínic de Barcelona and the CSIC to advance development over the next three years. Under that arrangement Genoma España committed a minimum of €3 million and access to industrialization capacity, including Histocell’s advanced therapy manufacturing plant in Derio. Research began in 2004, was patented in 2005, and entered Genoma España’s technology portfolio in 2008; animal models showed certain lung cells could help recover lost pulmonary function. Histocell has an ongoing clinical program in patients with moderate fibrosis supported financially by Genoma España, the Instituto de Salud Carlos III and the CSIC, with results expected during 2012. The company plans to launch a capital‑increase round to fund later clinical development phases.

No current team members are available.